Journal article

Pancytopenia in an adult patient with thiamine-responsive megaloblastic anaemia.

  • Moulin V Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
  • Grandoni F Department of Hematology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
  • Castioni J Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
  • Lu H Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Show more…
  • 2018-06-16
Published in:
  • BMJ case reports. - 2018
English Thiamine-responsive megaloblastic anaemia (TRMA) is a syndrome associated with megaloblastic anaemia, diabetes mellitus and sensorineural deafness, due to mutations in the SLC19A2 gene, which codes for a thiamine carrier protein. Oral thiamine supplementation is the main treatment. We report the case of a 25-year-old woman known for TRMA, who presented with pancytopenia (haemoglobin 7.6 g/dL, leucocytes 2.9×109/L, thrombocytes 6×109/L) revealed by dyspnoea. Investigations excluded coagulopathy, a recent viral infection, vitamin and iron deficiencies, and a malignant process. We later found out that thiamine treatment had been discontinued 5 weeks before, due to prescription error. Parenteral thiamine administration resulted in the recovery of haematopoiesis within 3 weeks. Pancytopenia is uncommon in patients with TRMA. Pre-existing medullary impairment caused by the patient's daily antipsychotic medications or the natural course of the syndrome may explain the severity of the laboratory findings in our patient.
Language
  • English
Open access status
green
Identifiers
Persistent URL
https://sonar.ch/global/documents/295691
Statistics

Document views: 20 File downloads:
  • fulltext.pdf: 0